:
1 - of resultados para ""
No results
First Line NSCLC Immunotherapy:
Patient Diversity and Treatment Options
17 MARZO 2021
17:30h - 19:45h
Join the virtual Panel Discussion
We invite you to join the scientific discussion of the complex treatment landscape in 1L NSCLC
with the international panel of top experts in the thoracic oncology field.
17:30 (CET)
Live online discussion with audience Q&A.
19:00 (CET)
Breakout sessions for personal interactions with panelists.
Our panelists
Mark A. Socinski is the Executive Medical Director for the AdventHealth Research center in the United States. He serves on the Respiratory Core Committee of the Cancer and Leukemia Group B (Alliance) and has been instrumental in the development of many cooperative clinical trials tackling advanced NSCLC and SCLC.
Solange Peters serves on the ESMO Executive Board as president for 2020. She is currently in charge of teaching and patient care in the area of medical oncology and thoracic malignancies at the Department of Oncology of Lausanne University, Switzerland. Her focus is on multimodality trial building for locally-advanced NSCLC as well as cancer immunotherapy.
Tim Benepal is Consultant Medical Oncologist at St George‘s and Parkside Hospital, UK. As an oncologist for 20 years Dr. Benepal is also lead lecturer for St George’s undergraduate and postgraduate medical students.
Dr. Ponce is responsible for the thoracic tumors unit at Hospital 12 de Octubre in collaboration with Dr. Paz - Ares. He is also the scientific coordinator of Oncosur Group, a foundation dedicated to promoting medical education and independent clinical investigation. Currently, he is working at institut Gustave Roussy in the therapeutic innovation and early phases trials department.
Guy Berchem practices as medical oncologist at Centre Hospitalier de Luxembourg heading its Oncology department as well as CAT committee member at the European medicines agency EMA. He is co-founder and associated Medical Director at the Luxembourg National Institute of Health.
Martin Reck is head of the oncological department at LungenClinic Grosshansdorf, Germany. He is internationally recognised for his notion of pneumology and oncology membering several specialist societies as ASCO, ESMO and DGP.
Barbara Melosky is a Professor of Medicine at the University of British Columbia and a Medical Oncologist at BC Cancer in Vancouver, Canada. She published in this area and is considered an international expert chairing several multi-disciplinary lung cancer congregations. Her main clinical research focus is on EGFR inhibitors and management of side effects.
Johan F. Vansteenkiste heads the Respiratory Oncology Unit and its Clinical Trial Unit at Leuven University Hospital, Belgium. He is a member of the ESMO Lung Educational Group and Guidelines Group, and appointed Chair of the European Lung Cancer Conference.
Georg Pall coordinates the oncological area at Universitätsklinik für Innere Medizin V Innsbruck, Austria. He is strongly monitoring developments in cancer immunology with a special focus on thoracic tumors.
Kerstin Ebel currently serves as Director of Medical Affairs at Roche Pharma (Schweiz) AG, Switzerland. She is a physician by training, graduated from the University of Freiburg and completed her doctorate at the University of Hamburg. Over the years she held multiple leadership positions within the Roche Global as well as affiliate organizations.
M-ES-00002693
